Management of patients with malignancies and secondary immunodeficiencies treated with immunoglobulins in clinical practice: Long-term data of the SIGNS study.

Marcel ReiserMichael BorteDörte HuscherUlrich BaumannDavid PittrowClaudia SommerMartin StangelMaria FasshauerRalf GoldManfred Hensel

Published in: European journal of haematology (2017)

Under clinical practice conditions, IG replacement therapy in SID patients was feasible, diminished infection rates and improved quality of life. Average IG doses were relatively low. Tolerability of IV IG treatment was excellent.

Keyphrases

clinical practice
replacement therapy
end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
smoking cessation
open label
peritoneal dialysis
prognostic factors
randomized controlled trial
machine learning
big data
combination therapy
artificial intelligence
double blind
patient reported